Nahdi Medical (TADAWUL:4164) Second Quarter 2025 Results

Key Financial Results

• Revenue: ر.س2.53b (up 2.2% from 2Q 2024).
• Net income: ر.س238.4m (down 3.8% from 2Q 2024).
• Profit margin: 9.4% (in line with 2Q 2024).
• EPS: ر.س1.83 (down from ر.س1.91 in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nahdi Medical Earnings Insights

Looking ahead, revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Consumer Retailing industry in Saudi Arabia.

The company's shares are down 6.5% from a week ago.

Risk Analysis

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.